Joseph Schlessinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4830420/publications.pdf

Version: 2024-02-01

210 papers

53,243 citations

99 h-index 208 g-index

214 all docs

214 docs citations

times ranked

214

48019 citing authors

#	Article	IF	CITATIONS
1	Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203-212.	13.5	5,482
2	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2010, 141, 1117-1134.	13.5	4,613
3	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000, 103, 211-225.	13.5	3,724
4	Cellular signaling by fibroblast growth factor receptors. Cytokine and Growth Factor Reviews, 2005, 16, 139-149.	3.2	1,677
5	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	13.7	1,610
6	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 1985, 313, 144-147.	13.7	1,464
7	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	3.3	1,206
8	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 2012, 44, 1006-1014.	9.4	1,052
9	Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science, 1997, 276, 955-960.	6.0	1,047
10	Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. Molecular Cell, 2000, 6, 743-750.	4.5	1,024
11	A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature, 1996, 383, 547-550.	13.7	956
12	Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 1995, 373, 536-539.	13.7	932
13	Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor. Cell, 2002, 110, 669-672.	13.5	906
14	Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell, 1987, 51, 1063-1070.	13.5	647
15	Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Cell, 1995, 83, 1037-1046.	13.5	613
16	Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature, 1993, 363, 88-92.	13.7	580
17	Structural Basis for FGF Receptor Dimerization and Activation. Cell, 1999, 98, 641-650.	13.5	575
18	PDGF stimulation of inositol phospholipid hydrolysis requires PLC- \hat{I}^31 phosphorylation on tyrosine residues 783 and 1254. Cell, 1991, 65, 435-441.	13.5	570

#	Article	IF	Citations
19	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 2017, 7, 1420-1435.	7.7	507
20	Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?. Cell, 1995, 83, 357-360.	13.5	484
21	Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature, 2010, 464, 783-787.	13.7	478
22	Absence of marginal zone B cells in Pyk-2–deficient mice defines their role in the humoral response. Nature Immunology, 2000, 1, 31-36.	7.0	476
23	PH Domains: Diverse Sequences with a Common Fold Recruit Signaling Molecules to the Cell Surface. Cell, 1996, 85, 621-624.	13.5	473
24	Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell, 1994, 78, 949-961.	13.5	469
25	Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in Biochemical Sciences, 1994, 19, 459-463.	3.7	438
26	SH2/SH3 signaling proteins. Current Opinion in Genetics and Development, 1994, 4, 25-30.	1.5	432
27	Switching Signals On or Off by Receptor Dimerization. Cell, 1998, 94, 277-280.	13.5	401
28	The carbonic anhydrase domain of receptor tyrosine phosphatase \hat{l}^2 is a functional ligand for the axonal cell recognition molecule contactin. Cell, 1995, 82, 251-260.	13.5	397
29	Signal transduction by allosteric receptor oligomerization. Trends in Biochemical Sciences, 1988, 13, 443-447.	3.7	386
30	Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors. Science, 2004, 306, 1506-1507.	6.0	384
31	Signal Transduction Due to HIV-1 Envelope Interactions with Chemokine Receptors CXCR4 or CCR5. Journal of Experimental Medicine, 1997, 186, 1793-1798.	4.2	383
32	Collection of insulin, EGF and $\hat{l}\pm 2$ -Macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell, 1978, 14, 805-810.	13.5	382
33	Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism. Cell, 1996, 86, 577-587.	13.5	378
34	Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity. Cell, 2000, 101, 413-424.	13.5	370
35	How receptor tyrosine kinases activate ras. Trends in Biochemical Sciences, 1993, 18, 273-275.	3.7	367
36	Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature, 1993, 366, 583-585.	13.7	363

#	Article	IF	CITATIONS
37	Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure, 2004, 12, 2233-2247.	1.6	360
38	Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature, 1998, 393, 812-817.	13.7	354
39	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics, 2015, 47, 996-1002.	9.4	348
40	The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases. Cold Spring Harbor Perspectives in Biology, 2014, 6, a020768-a020768.	2.3	345
41	A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling. Molecular and Cellular Biology, 2000, 20, 1448-1459.	1.1	334
42	Local aggregation of hormone–receptor complexes is required for activation by epidermal growth factor. Nature, 1979, 278, 835-838.	13.7	293
43	Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor. Cell, 2007, 130, 323-334.	13.5	290
44	The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development. Cell, 2000, 102, 211-220.	13.5	288
45	Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell, 1993, 73, 541-554.	13.5	277
46	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2916-2921.	3.3	275
47	New Roles for Src Kinases in Control of Cell Survival and Angiogenesis. Cell, 2000, 100, 293-296.	13.5	274
48	A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases. Molecular Cell, 2004, 15, 279-286.	4.5	271
49	Autoregulatory Mechanisms in Protein-tyrosine Kinases. Journal of Biological Chemistry, 1998, 273, 11987-11990.	1.6	262
50	Receptor Tyrosine Kinases: Legacy of the First Two Decades. Cold Spring Harbor Perspectives in Biology, 2014, 6, a008912-a008912.	2.3	255
51	Identification of the Binding Site for Acidic Phospholipids on the PH Domain of Dynamin: Implications for Stimulation of GTPase Activity. Journal of Molecular Biology, 1996, 255, 14-21.	2.0	251
52	A putative molecular-activation switch in the transmembrane domain of erbB2. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15937-15940.	3.3	247
53	Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface. Molecular and Cellular Biology, 2005, 25, 7734-7742.	1.1	247
54	Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. Structure, 1994, 2, 423-438.	1.6	239

#	Article	IF	Citations
55	SH2 and PTB Domains in Tyrosine Kinase Signaling. Science Signaling, 2003, 2003, re12-re12.	1.6	228
56	Regulation of Cell Proliferation by Epidermal Growth Factor. Critical Reviews in Biochemistry, 1983, 14, 93-111.	7.5	227
57	Scanning electron microscopy of cells and tissues under fully hydrated conditions. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3346-3351.	3.3	221
58	A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotechnology, 2005, 23, 201-207.	9.4	220
59	PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation. Current Biology, 1994, 4, 702-708.	1.8	216
60	Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities. ELife, 2014, 3, .	2.8	214
61	The Drosophila EGF receptor gene homolog: Conservation of both hormone binding and kinase domains. Cell, 1985, 40, 599-607.	13.5	213
62	Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in <i>Pyk2â^'/â^'</i> mice. Journal of Cell Biology, 2007, 178, 1053-1064.	2.3	208
63	Autophosphorylation of FGFR1 Kinase Is Mediated by a Sequential and Precisely Ordered Reaction. Molecular Cell, 2006, 21, 711-717.	4.5	203
64	Mobility of microinjected rhodamine actin within living chicken gizzard cells determined by fluorescence photobleaching recovery. Cell, 1982, 29, 835-845.	13.5	201
65	Mutations in different components of FGF signaling in LADD syndrome. Nature Genetics, 2006, 38, 414-417.	9.4	190
66	Src and Pyk2 Mediate G-protein-coupled Receptor Activation of Epidermal Growth Factor Receptor (EGFR) but Are Not Required for Coupling to the Mitogen-activated Protein (MAP) Kinase Signaling Cascade. Journal of Biological Chemistry, 2001, 276, 20130-20135.	1.6	187
67	Tyrosine Phosphorylation of the c-cbl Proto-oncogene Protein Product and Association with Epidermal Growth Factor (EGF) Receptor upon EGF Stimulation. Journal of Biological Chemistry, 1995, 270, 20242-20245.	1.6	182
68	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	3.3	181
69	A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor. Nature, 1986, 324, 68-70.	13.7	170
70	Induction of Neurite Outgrowth through Contactin and Nr-CAM by Extracellular Regions of Glial Receptor Tyrosine Phosphatase \hat{l}^2 . Journal of Cell Biology, 1997, 136, 907-918.	2.3	168
71	Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 935-940.	3.3	168
72	The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biology, 2004, 2, 24.	1.7	167

#	Article	IF	CITATIONS
73	Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain binding. Biochemistry, 1993, 32, 3197-3202.	1.2	165
74	Design of protein-binding proteins from the target structure alone. Nature, 2022, 605, 551-560.	13.7	164
75	FRS2Â attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6684-6689.	3.3	160
76	Structures of β-klotho reveal a â€~zip code'-like mechanism for endocrine FGF signalling. Nature, 2018, 553, 501-505.	13.7	160
77	Tyrosine Phosphorylation of Pyk2 Is Selectively Regulated by Fyn During TCR Signaling. Journal of Experimental Medicine, 1997, 185, 1253-1260.	4.2	158
78	Early and multiple origins of metastatic lineages within primary tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2140-2145.	3.3	157
79	RAC1 ^{P29S} is a spontaneously activating cancer-associated GTPase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 912-917.	3.3	146
80	Regression of Chemotherapy-Resistant Polymerase $\ddot{l}\mu$ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clinical Cancer Research, 2016, 22, 5682-5687.	3.2	145
81	Lateral motion and valence of Fc receptors on rat peritoneal mast cells. Nature, 1976, 264, 550-552.	13.7	143
82	The Docking Protein FRS2α Controls a MAP Kinase-Mediated Negative Feedback Mechanism for Signaling by FGF Receptors. Molecular Cell, 2002, 10, 709-719.	4.5	142
83	The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site. Cell, 2009, 138, 514-524.	13.5	142
84	Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4419-4424.	3.3	140
85	Anti-Epidermal Growth Factor Receptor Antibodies Inhibit the Autocrine-Stimulated Growth of MDA-468 Human Breast Cancer Cells. Molecular Endocrinology, 1989, 3, 1830-1838.	3.7	138
86	Identification of a Novel Family of Targets of PYK2 Related to <i>Drosophila</i> Retinal Degeneration B (rdgB) Protein. Molecular and Cellular Biology, 1999, 19, 2278-2288.	1.1	133
87	A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nature Genetics, 2002, 32, 411-414.	9.4	132
88	Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN- \hat{l}^3 , but not IFN- \hat{l}^4 , signaling. EMBO Journal, 1999, 18, 2480-2488.	3.5	131
89	Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E493-E502.	1.8	131
90	The mechanism and role of hormone-induced clustering of membrane receptors. Trends in Biochemical Sciences, 1980, 5, 210-214.	3.7	129

#	Article	IF	Citations
91	Augmentor $\hat{l}\pm$ and \hat{l}^2 (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligandâ \in "receptor interactions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15862-15867.	3.3	125
92	The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations. Science Signaling, 2009, 2, ra6.	1.6	123
93	Shc Binding to Nerve Growth Factor Receptor Is Mediated by the Phosphotyrosine Interaction Domain. Journal of Biological Chemistry, 1995, 270, 15125-15129.	1.6	122
94	Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase \hat{l}^2 . Current Opinion in Neurobiology, 1998, 8, 117-127.	2.0	121
95	Identification of a New Pyk2 Isoform Implicated in Chemokine and Antigen Receptor Signaling. Journal of Biological Chemistry, 1998, 273, 14301-14308.	1.6	121
96	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	5.8	113
97	SIGNAL TRANSDUCTION: Autoinhibition Control. Science, 2003, 300, 750-752.	6.0	112
98	A structure-based model for ligand binding and dimerization of EGF receptors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 929-934.	3.3	111
99	Onset of endogenous synthesis of epidermal growth factor in neonatal mice. Developmental Biology, 1987, 119, 38-44.	0.9	110
100	FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nature Communications, 2015, 6, 6980.	5.8	106
101	Asymmetric Tyrosine Kinase Arrangements in Activation or Autophosphorylation of Receptor Tyrosine Kinases. Molecules and Cells, 2010, 29, 443-448.	1.0	105
102	Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos. Nature Structural and Molecular Biology, 1994, 1, 891-897.	3.6	103
103	Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18866-18871.	3.3	100
104	Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9796-9801.	3.3	99
105	Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor. Journal of Biological Chemistry, 1997, 272, 6311-6317.	1.6	98
106	The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. Cell, 2016, 164, 1172-1184.	13.5	97
107	Multi-ligand interactions with receptor-like protein tyrosine phosphatase \hat{l}^2 : implications for intercellular signaling. Trends in Biochemical Sciences, 1998, 23, 121-124.	3.7	96
108	The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 923-928.	3.3	96

#	Article	IF	Citations
109	Reduced Activation of RAF-1 and MAP Kinase by a Fibroblast Growth Factor Receptor Mutant Deficient in Stimulation of Phosphatidylinositol Hydrolysis. Journal of Biological Chemistry, 1995, 270, 5065-5072.	1.6	94
110	Molecular basis of negative co-operativity in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. Journal of Molecular Biology, 1974, 82, 547-561.	2.0	93
111	The expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system. Developmental Brain Research, 1993, 75, 293-298.	2.1	92
112	On the nature of low- and high-affinity EGF receptors on living cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5735-5740.	3.3	91
113	The biochemical response of the heart to hypertension and exercise. Trends in Biochemical Sciences, 2004, 29, 609-617.	3.7	89
114	Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1906-1911.	3.3	89
115	Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring. Cell, 2006, 127, 45-48.	13.5	87
116	Direct Binding and Activation of Receptor Tyrosine Kinases by Collagen. Cell, 1997, 91, 869-872.	13.5	83
117	Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12027-12032.	3.3	78
118	Disulfide Bond Structure of Human Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 1998, 273, 11150-11157.	1.6	77
119	The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Pathway. Molecular and Cellular Biology, 2004, 24, 5657-5666.	1.1	76
120	Solution structure and ligand–binding site of the carboxy–terminal SH3 domain of GRB2. Structure, 1994, 2, 1029-1040.	1.6	74
121	'Tuning' of type I interferon–induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nature Immunology, 2008, 9, 186-193.	7.0	74
122	Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16107-16112.	3.3	73
123	Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Science Signaling, 2015, 8, ra6.	1.6	72
124	Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7681-7686.	3.3	71
125	FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Letters, 2004, 564, 14-18.	1.3	68
126	Pyk2 Is Required for Neutrophil Degranulation and Host Defense Responses to Bacterial Infection. Journal of Immunology, 2011, 186, 1656-1665.	0.4	68

#	Article	IF	Citations
127	Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor. Growth Factors, 2000, 18, 11-29.	0.5	67
128	Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2866-2871.	3.3	66
129	Insulin and antibodies against insulin receptor cap on the membrane of cultured human lymphocytes. Nature, 1980, 286, 729-731.	13.7	65
130	Lacrimo-Auriculo-Dento-Digital Syndrome Is Caused by Reduced Activity of the Fibroblast Growth Factor 10 (FGF10)-FGF Receptor 2 Signaling Pathway. Molecular and Cellular Biology, 2007, 27, 6903-6912.	1.1	64
131	Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide. Journal of Molecular Biology, 1999, 289, 439-445.	2.0	63
132	A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins. Biochemical and Biophysical Research Communications, 1981, 101, 517-523.	1.0	62
133	Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2010, 53, 1662-1672.	2.9	60
134	Scratching the surface with the PH domain. Nature Structural and Molecular Biology, 1995, 2, 715-718.	3.6	59
135	Solution structure of Grb2 reveals extensive flexibility necessary for target recognition11Edited by P. E. Wright. Journal of Molecular Biology, 2001, 306, 527-537.	2.0	59
136	Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3937-3942.	3.3	57
137	Ligand-Binding Enhances the Affinity of Dimerization of the Extracellular Domain of the Epidermal Growth Factor Receptor. Journal of Biochemistry, 1997, 122, 116-121.	0.9	55
138	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	3.3	52
139	Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16234-16239.	3.3	50
140	Variations of Proline-Rich Kinase Pyk2 Expression Correlate with Prostate Cancer Progression. Laboratory Investigation, 2001, 81, 51-59.	1.7	49
141	An FGF4-FRS2α-Cdx2 Axis in Trophoblast Stem Cells Induces BMP4 to Regulate Proper Growth of Early Mouse Embryos. Stem Cells, 2009, 28, N/A-N/A.	1.4	49
142	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 619-624.	3.3	49
143	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	3.3	48
144	Mitogenic Effects of Fibroblast Growth Factors in Cultured Fibroblastsa Annals of the New York Academy of Sciences, 1991, 638, 161-166.	1.8	45

#	Article	IF	Citations
145	Receptor Protein Tyrosine Phosphatase \hat{I}^3 Is a Marker for Pyramidal Cells and Sensory Neurons in the Nervous System and Is Not Necessary for Normal Development. Molecular and Cellular Biology, 2006, 26, 5106-5119.	1.1	40
146	Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4558-66.	3.3	40
147	Close Similarity between Drosophila Neurexin IV and Mammalian Caspr Protein Suggests a Conserved Mechanism for Cellular Interactions. Cell, 1997, 88, 745-746.	13.5	38
148	Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2. Biochemical and Biophysical Research Communications, 2009, 383, 347-352.	1.0	38
149	Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Medicinal Chemistry Letters, 2017, 8, 618-621.	1.3	38
150	Monoclonal antibodies associated with sodium channel block nerve impulse and stain nodes of Ranvier. Brain Research, 1984, 310, 168-173.	1.1	36
151	Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13225-13230.	3.3	36
152	Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19802-19807.	3.3	35
153	Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1772-1777.	3.3	35
154	Subcellular distribution of the external and internal domains of the EGF receptor in A-431 cells. Experimental Cell Research, 1986, 166, 312-326.	1.2	33
155	Thermodynamic Studies of SHC Phosphotyrosine Interaction Domain Recognition of the NPXpY Motif. Journal of Biological Chemistry, 1996, 271, 4770-4775.	1.6	33
156	FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Journal of Clinical Investigation, 2009, 119, 1077-1079.	3.9	32
157	FRS2α Regulates Erk Levels to Control a Self-Renewal Target Hes1 and Proliferation of FGF-Responsive Neural Stem/Progenitor Cells. Stem Cells, 2010, 28, 1661-1673.	1.4	30
158	Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature, 2021, 600, 153-157.	13.7	28
159	Structures of ligand-occupied \hat{l}^2 -Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7819-7824.	3.3	27
160	Characterization of the submicroscopic deletion in the small-cell lung carcinoma (SCLC) cell line U2020. Genes Chromosomes and Cancer, 1992, 5, 67-74.	1.5	26
161	The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell, 2015, 57, 191-201.	4.5	26
162	JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules. ACS Medicinal Chemistry Letters, 2017, 8, 614-617.	1.3	26

#	Article	IF	CITATIONS
163	Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Oncogene, 1999, 18, 4647-4653.	2.6	25
164	Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17832-17837.	3.3	25
165	The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene, 1999, 18, 2908-2912.	2.6	24
166	Vav: A potential link between tyrosine kinases and Ras-like GTP ases in hematopoietic cell signaling. Bio Essays, 1993, 15, 179-183.	1.2	22
167	A solid base for assaying protein kinase activity. Nature Biotechnology, 2002, 20, 232-233.	9.4	22
168	Induction of Urokinase-type Plasminogen Activator by Fibroblast Growth Factor (FGF)-2 Is Dependent on Expression of FGF Receptors and Does Not Require Activation of Phospholipase Cl³1. Journal of Biological Chemistry, 1996, 271, 31154-31159.	1.6	21
169	Structural basis for ligand reception by anaplastic lymphoma kinase. Nature, 2021, 600, 148-152.	13.7	21
170	The docking protein FRS2 \hat{l} ± is a critical regulator of VEGF receptors signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5514-5519.	3.3	20
171	Conformation of an Shc-derived phosphotyrosine-containing peptide complexed with the Grb2 SH2 domain. Journal of Biomolecular NMR, 1997, 10, 273-278.	1.6	19
172	Small molecule combats cancer-causing KRAS protein at last. Nature, 2019, 575, 294-295.	13.7	19
173	Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways. Oncogene, 1998, 16, 2425-2434.	2.6	18
174	Surface Binding Inhibitors of the SCF–KIT Protein–Protein Interaction. ChemBioChem, 2009, 10, 1955-1958.	1.3	18
175	Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4784-93.	3.3	18
176	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research, 2018, 24, 4845-4853.	3.2	18
177	FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with $\hat{l}\pm$ -Klotho. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31800-31807.	3.3	18
178	Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core. Journal of Medicinal Chemistry, 2020, 63, 5324-5340.	2.9	17
179	All Signaling Is Local?. Molecular Cell, 2002, 10, 218-219.	4.5	16
180	Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells. Methods in Enzymology, 1989, 168, 481-493.	0.4	15

#	Article	IF	CITATIONS
181	Definition of Signals for Neuronal Differentiation. Annals of the New York Academy of Sciences, 1995, 766, 1-17.	1.8	14
182	Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecologic Oncology Reports, 2015 , 12 , $3-4$.	0.3	14
183	The dynamic interrelationships of actin and vinculin in cultured cells. Cell Motility, 1983, 3, 399-403.	1.9	13
184	Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor- $\hat{l}\pm$). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8340-8345.	3.3	12
185	Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors. Tetrahedron Letters, 2011, 52, 2228-2231.	0.7	11
186	Identification of a Novel 135-kDa Grb2-binding Protein in Osteoclasts. Journal of Biological Chemistry, 1996, 271, 33141-33147.	1.6	9
187	Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31914-31922.	3.3	9
188	5. Fluorescence Methods for Studying Membrane Dynamics. Methods in Experimental Physics, 1982, 20, 197-227.	0.1	8
189	One Bead, One Chemical Compound: Use of the Selectide Process for Anticancer Drug Discovery. Acta Oncol \tilde{A}^3 gica, 1994, 33, 127-131.	0.8	8
190	A hypothalamic pathway for Augmentor α–controlled body weight regulation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200476119.	3.3	8
191	DYNAMICS OF HORMONE RECEPTORS ON CELL MEMBRANE. Annals of the New York Academy of Sciences, 1981, 366, 274-284.	1.8	7
192	Interaction of Epidermal Growth Factor with Vasoactive Hormones in the Regulation of Phospholipase A2. Journal of Basic and Clinical Physiology and Pharmacology, 1991, 2, 161-182.	0.7	7
193	Novel fluorescent approaches for studying cell signaling in single cells. Nature Biotechnology, 2000, 18, 262-263.	9.4	7
194	The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. Journal of Cell Biology, 2012, 199, 15-19.	2.3	7
195	Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in <scp>FGFR</scp> 1 kinase domain. Genes To Cells, 2015, 20, 860-870.	0.5	7
196	Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant. Tetrahedron Letters, 2021, 77, 153248.	0.7	7
197	Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands. Journal of Medicinal Chemistry, 2022, 65, 8380-8400.	2.9	7
198	Mobilities of cell-membrane proteins: how are they modulated by the cytoskeleton?. Trends in Neurosciences, 1983, 6, 360-363.	4.2	6

#	Article	IF	CITATIONS
199	Solution Structure of the SH2 Domain of Grb2/Ash Complexed with EGF Receptor-Derived Phosphotyrosine-Containing Peptide. Journal of Biochemistry, 1999, 125, 1151-1159.	0.9	6
200	A step towards treating KRAS-mutant NSCLC. Lancet Oncology, The, 2013, 14, 3-5.	5.1	6
201	Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies. ACS Medicinal Chemistry Letters, 2022, 13, 819-826.	1.3	6
202	[36] Use of tyrosine-phosphorylated proteins to screen bacterial expression libraries for SH2 domains. Methods in Enzymology, 1995, 255, 360-369.	0.4	5
203	Use of Large Combinatorial Chemical Libraries for Anticancer Drug Discovery. International Journal of Pharmacognosy, 1995, 33, 67-74.	0.2	4
204	Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain. Genes To Cells, 2016, 21, 350-357.	0.5	3
205	Reminiscences on the "Classic" 1976 FRAP Article in Biophysical Journal. Biophysical Journal, 2018, 115, 1156-1159.	0.2	3
206	Cloning, Expression of the Human Substance K Receptor, and Analysis of Its Role in Mitogenesis. Annals of the New York Academy of Sciences, 1991, 632, 426-427.	1.8	2
207	Identification of the Bombesin Receptor on Murine and Human Cells by Cross-Linking Experiments. Annals of the New York Academy of Sciences, 1988, 547, 474-476.	1.8	0
208	Signal transduction by EGF-receptor and ist mutants. Cell Differentiation and Development, 1989, 27, 114.	0.4	0
209	Spontaneously Formed EGFR Dimers Are Primed For Activation. Biophysical Journal, 2009, 96, 368a.	0.2	O
210	Tony Pawson (1952–2013). Cell, 2013, 154, 1180-1181.	13.5	0